GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (LTS:0KF3) » Definitions » Gross Profit

Palatin Technologies (LTS:0KF3) Gross Profit : $5.70 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Palatin Technologies Gross Profit?

Palatin Technologies's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. Palatin Technologies's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $5.70 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Palatin Technologies's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. Palatin Technologies's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Palatin Technologies's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Palatin Technologies had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of Palatin Technologies was 177.78%. The lowest was 85.22%. And the median was 91.37%.


Palatin Technologies Gross Profit Historical Data

The historical data trend for Palatin Technologies's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Gross Profit Chart

Palatin Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.30 0.12 -0.34 1.25 4.44

Palatin Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.66 2.11 1.94 -

Competitive Comparison of Palatin Technologies's Gross Profit

For the Biotechnology subindustry, Palatin Technologies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palatin Technologies's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Gross Profit distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Gross Profit falls into.



Palatin Technologies Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Palatin Technologies's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=4.854 - 0.419
=4.44

Palatin Technologies's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.70 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Palatin Technologies's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Palatin Technologies  (LTS:0KF3) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Palatin Technologies had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Palatin Technologies Gross Profit Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Palatin Technologies (LTS:0KF3) Business Description

Traded in Other Exchanges
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Palatin Technologies (LTS:0KF3) Headlines

No Headlines